abemaciclib + gemcitabine

Abemaciclib + gemcitabine is a **combination therapy** consisting of abemaciclib, a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), and gemcitabine, a nucleoside analog that inhibits DNA synthesis. - **Abemaciclib** blocks CDK4/6 activity, leading to cell cycle arrest at the G1 phase and inhibition of cancer cell proliferation. - **Gemcitabine** is phosphorylated inside cells and incorporated into DNA, causing chain termination and cell death, primarily targeting rapidly dividing cells. This combination is being investigated primarily for advanced and metastatic cancers, such as non-small cell lung cancer (NSCLC)[1][4]. Abemaciclib is developed and manufactured by Eli Lilly, while gemcitabine is a generic product, originally developed by Eli Lilly, and now manufactured by various companies worldwide[5].

Other names

abemaciclibgemcitabine